Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03209362 · ClinicalTrials.gov registry record · Phase 2
SI-613 Study for Knee Osteoarthritis
A Phase 2 study, sponsored by Seikagaku Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03209362 is a Phase 2 study that has completed, run by Seikagaku Corporation. The registered enrollment target is 80 participants.
The verdict
NCT03209362, a Phase 2 study, has completed, sponsored by Seikagaku Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the efficacy and safety of intra-articular injections of SI-613 compared with placebo for knee OA.
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT SI-613
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2018-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03209362
The ClinicalTrials.gov registry entry for NCT03209362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seikagaku Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03209362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03209362 about?
NCT03209362 is a clinical study titled "SI-613 Study for Knee Osteoarthritis". The objective of the study is to evaluate the efficacy and safety of intra-articular injections of SI-613 compared with placebo for knee OA.
What is the current status of trial NCT03209362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-10-19. Estimated completion is 2018-11-13.
What interventions are being tested in trial NCT03209362?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), SI-613 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03209362?
This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.